Genetically Simulated GLP-1 Receptor Agonism and Cerebral Small Vessel Disease - PubMed
12 hours ago
- #GLP-1 receptor agonists
- #cerebral small vessel disease
- #Mendelian Randomization
- Cerebral small vessel disease (cSVD) is a common cause of stroke and dementia with no definitive treatments available.
- GLP-1 receptor agonists, used for diabetes and obesity, may reduce cardiovascular risk, but their effect on cSVD was unknown.
- A study used Mendelian Randomization (MR) to analyze genetic variants mimicking GLP-1R agonist effects on cSVD phenotypes.
- Primary outcomes included small vessel stroke and white matter hyperintensity (WMH) volume.
- Genetically proxied GLP-1R agonism was associated with lower odds of small vessel stroke and reduced WMH volume.
- Similar associations were found for genetically proxied BMI reduction linked to GLP1R.
- The findings suggest GLP-1 receptor agonists could be a potential strategy to prevent cSVD progression, warranting clinical trials.